Epinephrine has been part of cardiac arrest resuscitation since the 1960s. For most of that time, the rationale was straightforward: alpha-adrenergic stimulation increases coronary and cerebral perfusion pressure during CPR. More perfusion, better outcomes.
The 2020 AHA guidelines refined the picture considerably. Here's what changed — and what didn't.
"For shockable rhythms, electricity comes first. The vasopressor waits its turn."
The key numbers
What didn't change
Epinephrine 1mg IV/IO every 3–5 minutes remains standard for non-shockable rhythms (PEA and asystole). The evidence here is reasonably consistent: epinephrine improves ROSC rates in PEA/asystole. It works as a tool to buy time while you identify and treat reversible causes. Push early. Push consistently.
What the guidelines now say about shockable rhythms
For V-Fib and pulseless V-Tach, the 2020 guidelines recommend delaying epinephrine until after initial defibrillation attempts have failed. Specifically: shock first, then epinephrine if the rhythm remains shockable after the first or second shock.
Why the delay? Epinephrine's vasoconstrictive effects can actually reduce the chance of successful defibrillation in early V-Fib. The heart that's been in V-Fib for under two minutes responds better to electricity than to vasopressors. The beta-adrenergic effects increase myocardial oxygen demand precisely when the heart can least afford it.
This is a subtle but clinically significant shift from how many teams were trained. Teams that learned ACLS in the 2010 era often push epi reflexively after the first rhythm check, regardless of whether the rhythm is shockable. That's no longer best practice.
The amiodarone question
For refractory V-Fib — shock-resistant arrest — amiodarone 300mg IV remains the first antiarrhythmic of choice, with a second dose of 150mg if needed. Lidocaine is an acceptable alternative if amiodarone is unavailable. The evidence between the two is closer than many people realize, and neither has definitively shown a mortality benefit — but they're both reasonable tools when electricity alone isn't converting the rhythm.
Timing matters here too. The antiarrhythmic goes in after the third shock, not before. You're treating a heart that has repeatedly rejected defibrillation — that's a different clinical problem than early V-Fib, and the drugs target it specifically.
How ACLSMED trains this
In our Refractory V-Fib scenario, the timing of your epinephrine administration is tracked and scored. Administer it before the first shock in a fresh V-Fib and the simulator flags it as a protocol deviation. That's not punitive — it's the kind of feedback that cements the correct sequence in muscle memory.
The drug is simple. The timing is where the guidelines actually live.
Practice the sequence, not just the dose
Run the V-Fib Mega Code in the ACLSMED Clinical Suite. The simulator tracks when you push each drug and shows you exactly where your timing falls against the 2020 guidelines.
Launch the Simulator →